The 140-Year Journey of Menarini, the Italian Pharmaceutical Giant

As a traditional power in European biopharmaceutical manufacturing, Italy possesses outstanding technology, excellent products, and a comprehensive R&D system in the pharmaceutical field. Among them, the Menarini Group, as a leading company in the Italian pharmaceutical industry, ranks among the top European pharmaceutical companies and is among the global TOP50 pharmaceutical companies.

Since its establishment in 1886, the Menarini Group has always focused on pharmaceutical R&D in areas such as cardiovascular diseases, inflammatory analgesia, gastrointestinal diseases, oncology, and metabolic diseases. The company's headquarters is located in Florence, with over 17,700 employees worldwide, and has established subsidiaries, distributors, and franchises in 140 countries, forming a widespread and in-depth international business network.

In recent years, Menarini has continuously expanded its international business footprint. In 1992, it successfully entered the German and Central and Eastern European markets through the acquisition of Berlin-Chemie; in 2011, it acquired the Invida Group, further consolidating its market position in the Asia-Pacific region; and in 2020, it successfully entered the US oncology market through the acquisition of the biopharmaceutical company Stemline Therapeutics, demonstrating its strong market expansion capabilities and strategic vision.

In the fields of oncology and infectious diseases, Menarini is highly regarded for its innovative drugs and technology products. Its product line covers innovative drugs such as small molecules and biologics for the treatment of hematological malignancies and solid tumors. At the same time, the company is also actively investing in the development of diagnostic technologies, aiming to develop high-speed, high-precision diagnostic instruments covering clinical chemistry, diabetes, immunology, hematology, histology, and point-of-care testing.

Taking Tagraxofusp as an example, this drug is an important innovative achievement of Menarini in the field of cancer treatment. As a CD123-directed cytotoxin, it has been approved for the treatment of adult and pediatric patients (2 years and older) with blastic plasmacytoid dendritic cell neoplasm (BPDCN). As the first approved treatment for BPDCN and the first approved CD123-targeted drug, the launch of Tagraxofusp has brought new hope and choice for the clinical treatment of BPDCN patients.

In summary, as a leading company in the Italian pharmaceutical industry, Menarini, with its 140-year historical tradition and continuous innovation spirit, has achieved remarkable results in the fields of oncology and infectious diseases. The company is committed to providing patients with better treatment options and has demonstrated strong competitiveness and broad development prospects in the international market.